<DOC>
	<DOCNO>NCT00998270</DOCNO>
	<brief_summary>A prospective , randomized trial autologous bone marrow transplantation compare allogeneic bone marrow transplantation multiple myeloma .</brief_summary>
	<brief_title>Autologous Bone Marrow Transplantation ( BMT ) Compared With Allogeneic BMT Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Age diagnosis equal 55 year Meeting Durie Salmon criterion initial diagnosis MM Stage II III MM diagnosis anytime thereafter Symptomatic MM require treatment diagnosis anytime thereafter If receive chemotherapybased mobilization regimen , must able receive highdose melphalan 2 8 week initiation mobilization therapy whether deliver transplant center refer center Adequate organ function measure : Cardiac : Left ventricular ejection fraction rest great 40 % Hepatic : Bilirubin le 2 time upper limit normal ALT AST less 3 time upper limit normal Renal : Creatinine clearance great 40 ml/min ( measure calculated/estimated ) Pulmonary : DLCO , FEV1 , FVC great 50 % predict value ( correct hemoglobin ) , O2 saturation great 92 % room air An adequate autologous graft define cryopreserved PBSC graft contain least 4.0 x 10^6 CD34+ cells/kg patient weight ; prior enrollment know patient autoallo arm ( i.e. , consent , eligible HLAmatched sibling donor available ) , require autograft must contain least 2.0 x 10^6 CD34+ cells/kg patient weight ; graft may CD34+ select otherwise manipulate remove tumor cell ; graft collect transplant institution refer center ; patient without HLAmatched sibling donor , autograft must store two product contain least 2 x 10^6 CD34+ cells/kg patient weight Never advance beyond Stage I MM since diagnosis Nonsecretory MM ( absence monoclonal protein [ M protein ] serum measure electrophoresis immunofixation absence Bence Jones protein urine define use conventional electrophoresis immunofixation technique ) Plasma cell leukemia Karnofsky performance score le 70 % , unless approve Medical Monitor one Protocol Chairs Uncontrolled hypertension Uncontrolled bacterial , viral , fungal infection ( currently take medication progression clinical symptom ) Prior malignancy except resect basal cell carcinoma treat cervical carcinoma situ ; cancer treat curative intent le 5 year previously allow unless approve Medical Monitor one Protocol Chairs ; cancer treat curative intent 5 year previously allow Pregnant breastfeed Seropositive human immunodeficiency virus ( HIV ) Unwilling use contraceptive technique 12 month follow treatment Prior allograft prior autograft Received midintensity melphalan ( 50 mg IV ) part prior therapy Prior organ transplant require immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>MM</keyword>
</DOC>